Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 2020–2027

A06540
Pages: 329
Jun 2020 | 536 Views
 
Author(s) : Surabhi Pandey & Komal Urde , Onkar Sumant
Tables: 190
Charts: 62
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Oral Antibiotics Market

Request Now !

The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.

Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.

oral-antibiotics-market-2020-2027-1593695261

Get more information on this report : Request Sample Pages

The virus that causes COVID-19 is from the family of viruses called Coronaviridae and antibiotics do not work against them. However, some people who are affected by Covid-19 can also develop a bacterial infection as a complication. In this case, health care providers recommend antibiotics. Hence, the impact of Covid-19 on oral antibiotics industry is expected to be moderate.

There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type, and region. On the basis of class, it is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global oral antibiotics market include Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Segment review

Depending on class, the market is categorized into the beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018.  The segment is the major revenue contributor, owing to its broad-spectrum of activity. A broad-spectrum antibiotic fights both gram-negative and gram-positive bacteria as well as is effective on the multiple groups of bacterial infections. However, quinolone segment is expected to witness highest CAGRs during the forecast period, owing to its broad spectrum of activity and they are effective against a wide range of bacteria. 

Oral Antibiotics Market, by Class
By Class

Your browser does not support the canvas element.

Beta lactam & beta lactamase inhibitors is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

On the basis of application, the CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies. The urinary acquired tract infections segment was the highest contributor to the market in 2018, and expected to witness CAGR of 2.0% during the forecast period, as it is the most common hospital acquired infection accounting for almost 40% of all nosocomial infections and females are more likely to acquire UTI every year as compared to males. In addition, diabetic patients are also more prone to UTIs, mostly owing to abnormalities in immune function.

Oral Antibiotics Market, by Class
By Application

Your browser does not support the canvas element.

The UTIs segment generated the highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period.

Get more information on this report : Request Sample Pages

On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms. However, the synthetic segment is projected to show fastest growth during the forecast period, due to the rising need of synthetic membrane-targeted antibiotics due to the antimicrobial resistance. The synthetic antibiotics have various advantages over existing antibiotics such as a broad spectrum of activity, no cross-resistance with the existing antibiotics, rapid bactericidal activity, and a low probability for developing resistance.

Oral Antibiotics Market, by Class
By Drug Origin

Your browser does not support the canvas element.

The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period.

Get more information on this report : Request Sample Pages

Region wise, Asia-Pacific accounted for nearly two-fifths of the global market share in 2018 and is expected to remain dominant throughout the forecast period. This region is the world’s largest consumer of antibiotics, owing to large number of antibiotics consumption, easy availability of antibiotics, and rise in sales of antibiotics without prescription. However, LAMEA is expected to experience the highest growth rate during the forecast period. This is attributed to easy obtainability of over-the-counter antibiotics as well as there are no legislations or restrictions on their use in this region.

Oral Antibiotics Market, by Class
By Region

2027
Asia-pacific 
North America
Europe
Lamea

Asia-Pacific accounted for nearly two-fifths of the global market share in 2018 and is expected to remain dominant throughout the forecast period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2018 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities. 
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.

Key Market Segments

By Class

  • Beta Lactam and Beta Lactamase Inhibitors
    • Penicillin
      • Broad Spectrum Penicillin
      • Mid/Narrow Spectrum Penicillin
    • Cephalosporin
    • Others
  • Quinolone
  • Macrolide
  • Others

By Application

  • Community-respiratory tract infections (CARTIS)
    • Upper Respiratory Tract Infections (URTI)
    • Lower Respiratory Tract Infections (LRTI)
  • Urinary acquired tract infections (UTIS)
  • Dental
    • Combination
    • Monotherapies
  • Others

By Drug Origin

  • Natural
  • Semisynthetic
  • Synthetic

By Spectrum of Activity

  • Broad-spectrum Antibiotic
  • Narrow-spectrum Antibiotic

By Drug Type

  • Branded
  • Generic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • UK
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Pakistan
    • Vietnam
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Turkey
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Market share analysis, 2018
3.4.Porter’s five forces analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in consumption in low-and middle-income countries (LMICs) 
3.5.1.2.Rise in prevalence of infectious diseases
3.5.1.3.Development of novel approaches

3.5.2.Restraints

3.5.2.1.Development of antibiotic resistance
3.5.2.2.Time consuming approvals

3.5.3.Opportunities

3.5.3.1.Discovery of advanced therapies to treat antibiotic-resistance. 

3.6.Impact analysis of COVID-19 on oral antibiotics market

CHAPTER 4:ORAL ANTIBIOTICS MARKET, BY CLASS

4.1.Overview

4.1.1.Market size and forecast, by class

4.2.Beta lactam and beta lactamase inhibitors

4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Penicillin

4.2.2.1.1.Market size and forecast, by type

4.2.2.1.1.1.Broad-spectrum penicillin
4.2.2.1.1.2.Mid/Narrow-spectrum penicillin

4.2.2.2.Cephalosporin

4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by molecule

4.2.2.3.Others

4.2.2.3.1.Market size and forecast

4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country

4.3.Quinolones

4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Macrolides

4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Others

4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:ORAL ANTIBIOTICS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Community-acquired respiratory tract infections (CARTIs) 

5.2.1.Market size and forecast, by type

5.2.1.1.Upper Respiratory Tract Infections (URTI) 

5.2.1.1.1.Market size and forecast
5.2.1.1.2.Market size and forecast, by molecule

5.2.1.2.Lower Respiratory Tract Infections (LRTIs) 

5.2.1.2.1.Market size and forecast
5.2.1.2.2.Market size and forecast, by molecule

5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Urinary tract infections (UTIs) 

5.3.1.Market size and forecast, by molecule
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

5.4.Dental

5.4.1.Market size and forecast, by type

5.4.1.1.Combination

5.4.1.1.1.Market size and forecast
5.4.1.1.2.Market size and forecast, by molecule

5.4.1.2.Monotherapies

5.4.1.2.1.Market size and forecast
5.4.1.2.2.Market size and forecast, by molecule

5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

CHAPTER 6:ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN

6.1.Overview

6.1.1.Market size and forecast

6.2.Natural

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Semisynthetic

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Synthetic

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

7.1.Overview

7.1.1.Market size and forecast

7.2.Broad-spectrum antibiotic

7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country

7.3.Mid/Narrow-spectrum antibiotic

7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country

CHAPTER 8:ORAL ANTIBIOTICS MARKET, BY DRUG TYPE

8.1.Overview

8.1.1.Market size and forecast

8.2.Branded

8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country

8.3.Generics

8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country

CHAPTER 9:ORAL ANTIBIOTICS MARKET, BY REGION

9.1.Overview

9.1.1.Market size and forecast

9.2.North America

9.2.1.Key market trends and opportunities
9.2.2.North America antibiotics market, by country

9.2.2.1.U.S. oral antibiotics market, by class
9.2.2.2.U.S. oral antibiotics market, by application
9.2.2.3.U.S. oral antibiotics market, by drug origin
9.2.2.4.U.S. oral antibiotics market, by spectrum of activity
9.2.2.5.U.S. oral antibiotics market, by Drug type
9.2.2.6.Canada oral antibiotics market, by class

9.2.2.7.Canada oral antibiotics market, by application
9.2.2.8.Canada oral antibiotics market, by drug origin
9.2.2.9.Canada oral antibiotics market, by spectrum of activity
9.2.2.10.Canada oral antibiotics market, by drug type
9.2.2.11.Mexico oral antibiotics market, by class162
9.2.2.12.Mexico oral antibiotics market, by application
9.2.2.13.Mexico oral antibiotics market, by drug origin
9.2.2.14.Mexico oral antibiotics market, by spectrum of activity
9.2.2.15.Mexico oral antibiotics market, by drug type

9.2.3.North America oral antibiotics market, by class
9.2.4.North America oral antibiotics market, by application
9.2.5.North America oral antibiotics market, by drug origin
9.2.6.North America oral antibiotics market, by spectrum of activity
9.2.7.North America antibiotics market, by drug type

9.3.Europe

9.3.1.Key market trends and opportunities
9.3.2.Europe oral antibiotics market, by country

9.3.2.1.Germany oral antibiotics market, by class
9.3.2.2.Germany oral antibiotics market, by application
9.3.2.3.Germany oral antibiotics market, by drug origin
9.3.2.4.Germany oral antibiotics market, by spectrum of activity
9.3.2.5.Germany oral antibiotics market, by Drug type
9.3.2.6.France oral antibiotics market, by class
9.3.2.7.France oral antibiotics market, by application
9.3.2.8.France oral antibiotics market, by drug origin
9.3.2.9.France oral antibiotics market, by spectrum of activity
9.3.2.10.France oral antibiotics market, by drug type
9.3.2.11.Spain oral antibiotics market, by class181
9.3.2.12.Spain oral antibiotics market, by application
9.3.2.13.Spain oral antibiotics market, by drug origin
9.3.2.14.Spain oral antibiotics market, by spectrum of activity
9.3.2.15.Spain oral antibiotics market, by drug type
9.3.2.16.Italy oral antibiotics market, by class185
9.3.2.17.Italy oral antibiotics market, by application
9.3.2.18.Italy oral antibiotics market, by drug origin
9.3.2.19.Italy oral antibiotics market, by spectrum of activity
9.3.2.20.Italy oral antibiotics market, by drug type
9.3.2.21.UK oral antibiotics market, by class
9.3.2.22.UK oral antibiotics market, by application
9.3.2.23.UK oral antibiotics market, by drug origin
9.3.2.24.UK oral antibiotics market, by spectrum of activity
9.3.2.25.UK oral antibiotics market, by drug type
9.3.2.26.Russia oral antibiotics market, by class
9.3.2.27.Russia oral antibiotics market, by application
9.3.2.28.Russia oral antibiotics market, by drug origin
9.3.2.29.Russia oral antibiotics market, by spectrum of activity
9.3.2.30.Russia oral antibiotics market, by drug type
9.3.2.31.Rest of Europe oral antibiotics market, by class
9.3.2.32.Rest of Europe oral antibiotics market, by application
9.3.2.33.Rest of Europe oral antibiotics market, by drug origin
9.3.2.34.Rest of Europe oral antibiotics market, by spectrum of activity
9.3.2.35.Rest of Europe oral antibiotics market, by drug type

9.3.3.Europe oral antibiotics market, by class
9.3.4.Europe oral antibiotics market, by application
9.3.5.Europe oral antibiotics market, by drug origin
9.3.6.Europe oral antibiotics market, by spectrum of activity
9.3.7.Europe oral antibiotics market, by drug type

9.4.Asia-Pacific

9.4.1.Key market trends and opportunities
9.4.2.Asia-Pacific oral antibiotics market, by country

9.4.2.1.Japan oral antibiotics market, by class
9.4.2.2.Japan oral antibiotics market, by application
9.4.2.3.Japan oral antibiotics market, by drug origin
9.4.2.4.Japan oral antibiotics market, by spectrum of activity
9.4.2.5.Japan oral antibiotics market, by drug type
9.4.2.6.India oral antibiotics market, by class
9.4.2.7.India oral antibiotics market, by application
9.4.2.8.India oral antibiotics market, by drug origin
9.4.2.9.India oral antibiotics market, by spectrum of activity
9.4.2.10.India oral antibiotics market, by drug type
9.4.2.11.China oral antibiotics market, by class
9.4.2.12.China oral antibiotics market, by application
9.4.2.13.China oral antibiotics market, by drug origin
9.4.2.14.China oral antibiotics market, by spectrum of activity
9.4.2.15.China oral antibiotics market, by drug type
9.4.2.16.Pakistan oral antibiotics market, by class
9.4.2.17.Pakistan oral antibiotics market, by application
9.4.2.18.Pakistan oral antibiotics market, by drug origin
9.4.2.19.Pakistan oral antibiotics market, by spectrum of activity
9.4.2.20.Pakistan oral antibiotics market, by Drug type
9.4.2.21.Vietnam oral antibiotics market, by class
9.4.2.22.Vietnam oral antibiotics market, by application
9.4.2.23.Vietnam oral antibiotics market, by drug origin
9.4.2.24.Vietnam oral antibiotics market, by spectrum of activity
9.4.2.25.Vietnam oral antibiotics market, by Drug type
9.4.2.26.Rest of Asia-Pacific oral antibiotics market, by class
9.4.2.27.Rest of Asia-Pacific oral antibiotics market, by application
9.4.2.28.Rest of Asia-Pacific oral antibiotics market, by drug origin
9.4.2.29.Rest of Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.2.30.Rest of Asia-Pacific oral antibiotics market, by drug type

9.4.3.Asia-Pacific oral antibiotics market, by class
9.4.4.Asia-Pacific oral antibiotics market, by application
9.4.5.Asia-Pacific oral antibiotics market, by drug origin
9.4.6.Asia-Pacific oral antibiotics market, by spectrum of activity
9.4.7.Asia-Pacific oral antibiotics market, by drug type

9.5.LAMEA

9.5.1.Key market trends and opportunities
9.5.2.LAMEA antibiotics market, by country

9.5.2.1.Brazil oral antibiotics market, by class
9.5.2.2.Brazil oral antibiotics market, by application
9.5.2.3.Brazil oral antibiotics market, by drug origin
9.5.2.4.Brazil oral antibiotics market, by spectrum of activity
9.5.2.5.Brazil oral antibiotics market, by drug type
9.5.2.6.Saudi Arabia oral antibiotics market, by class
9.5.2.7.Saudi Arabia oral antibiotics market, by application
9.5.2.8.Saudi Arabia oral antibiotics market, by drug origin
9.5.2.9.Saudi Arabia oral antibiotics market, by spectrum of activity
9.5.2.10.Saudi Arabia oral antibiotics market, by application
9.5.2.11.South Africa oral antibiotics market, by class
9.5.2.12.South Africa oral antibiotics market, by application
9.5.2.13.South Africa oral antibiotics market, by drug origin
9.5.2.14.South Africa oral antibiotics market, by spectrum of activity
9.5.2.15.South Africa oral antibiotics market, by drug type
9.5.2.16.Turkey oral antibiotics market, by class
9.5.2.17.Turkey oral antibiotics market, by application
9.5.2.18.Turkey oral antibiotics market, by drug origin
9.5.2.19.Turkey oral antibiotics market, by spectrum of activity
9.5.2.20.Turkey oral antibiotics market, by drug type
9.5.2.21.Rest of LAMEA oral antibiotics market, by class
9.5.2.22.Rest of LAMEA oral antibiotics market, by application
9.5.2.23.Rest of LAMEA oral antibiotics market, by drug origin
9.5.2.24.Rest of LAMEA oral antibiotics market, by spectrum of activity
9.5.2.25.Rest of LAMEA oral antibiotics market, by drug type

9.5.3.LAMEA antibiotics market, by class
9.5.4.LAMEA antibiotics market, by application
9.5.5.LAMEA antibiotics market, by drug origin
9.5.6.LAMEA antibiotics market, by spectrum of activity
9.5.7.LAMEA antibiotics market, by drug type

CHAPTER 10:COMPANY PROFILES

10.1.ABBOTT LABORATORIES

10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance

10.2.ALLERGAN PLC

10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments

10.3.F. HOFFMANN-LA ROCHE LTD. 

10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance
10.3.6.Key strategic moves and developments

10.4.GLAXOSMITHKLINE PLC

10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.4.6.Key strategic moves and developments

10.5.MERCK & CO., INC. 

10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Business performance
10.5.6.Key strategic moves and developments

10.6.MYLAN N.V. 

10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments

10.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.) 

10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Operating business segments
10.7.4.Product portfolio
10.7.5.Business performance
10.7.6.Key strategic moves and developments

10.8.PFIZER INC. 

10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Operating Product
10.8.5.Business performance
10.8.6.Key strategic moves and developments

10.9.SANOFI

10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.9.6.Key strategic moves and developments

10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD. 

10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL ORAL ANTIBIOTICS MARKET, BY CLASS, 2018–2027 ($MILLION) 
TABLE 02.BETA LACTAM & BETA LACTAMASE INHIBITORS ANTIBIOTICS MARKET, BY TYPE, 2018–2027 ($MILLION) 
TABLE 03.PENICILLIN ORAL ANTIBIOTICS MARKET, BY TYPE, 2018–2027 ($MILLION) 
TABLE 04.ORAL ANTIBIOTICS MARKET FOR CEPHALOSPORIN, BY MOLECULE, 2018–2027 ($MILLION) 
TABLE 05.ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY REGION, 2018–2027 ($MILLION) 
TABLE 06.ANTIBIOTICS MARKET FOR QUINOLONES, BY REGION, 2018–2027 ($MILLION) 
TABLE 07.ANTIBIOTICS MARKET FOR MACROLIDES, BY REGION, 2018–2027 ($MILLION) 
TABLE 08.ANTIBIOTICS MARKET FOR OTHER CLASSES BY REGION, 2018–2027 ($MILLION) 
TABLE 09.GLOBAL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018–2027 ($MILLION) 
TABLE 10.ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY TYPE, 2018–2027 ($MILLION) 
TABLE 11.ORAL ANTIBIOTICS MARKET FOR UPPER RESPIRATORY TRACT INFECTIONS, BY MOLECULE, 2018–2027 ($MILLION) 
TABLE 12.ORAL ANTIBIOTICS MARKET FOR LOWER RESPIRATORY TRACT INFECTIONS, BY MOLECULE, 2018–2027 ($MILLION) 
TABLE 13.ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY REGION, 2018–2027 ($MILLION) 
TABLE 14.ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY MOLECULE, 2018–2027 ($MILLION) 
TABLE 15.ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY REGION, 2018–2027 ($MILLION) 
TABLE 16.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY TYPE, 2018–2027 ($MILLION) 
TABLE 17.ORAL ANTIBIOTICS MARKET FOR DENTAL COMBINATION ORAL ANTIBIOTICS, BY MOLECULE, 2018–2027 ($MILLION) 
TABLE 18.ORAL ANTIBIOTICS MARKET FOR DENTAL MONOTHERAPIES, BY MOLECULE, 2018–2027 ($MILLION) 
TABLE 19.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY REGION, 2018–2027 ($MILLION) 
TABLE 20.ORAL ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2018–2027 ($MILLION) 
TABLE 21.GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018–2027 ($MILLION) 
TABLE 22.ORAL ANTIBIOTICS MARKET FOR NATURAL, BY REGION, 2018–2027 ($MILLION) 
TABLE 23.ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY REGION, 2018–2027 ($MILLION) 
TABLE 24.ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY REGION, 2018–2027 ($MILLION) 
TABLE 25.GLOBAL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018–2027 ($MILLION) 
TABLE 26.ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ORAL ANTIBIOTIC, BY REGION, 2018–2027 ($MILLION)
TABLE 27.ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ORAL ANTIBIOTIC, BY REGION, 2018–2027 ($MILLION) 
TABLE 28.GLOBAL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018–2027 ($MILLION) 
TABLE 29.BRANDED ANTIBIOTICS MARKET, BY REGION, 2018–2027 ($MILLION)TABLE 30.GENERIC ANTIBIOTICS MARKET, BY REGION, 2018–2027 ($MILLION) 
TABLE 31.ORAL ANTIBIOTICS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION) 
TABLE 32.NORTH AMERICA ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION) 
TABLE 33.U.S. ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 34.U.S. ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 35.U.S. ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 36.U.S. ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 37.U.S. ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 38.CANADA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 39.CANADA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 40.CANADA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 41.CANADA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 42.CANADA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 43.MEXICO ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 44.MEXICO ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 45.MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 46.MEXICO ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 47.MEXICO ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 48.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 49.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 50.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 51.NORTH AMERICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 52.NORTH AMERICA ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 53.EUROPE ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION) 
TABLE 54.GERMANY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 55.GERMANY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 56.GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 57.GERMANY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 58.GERMANY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 59.FRANCE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 60.FRANCE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 61.FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 62.FRANCE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 63.FRANCE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 64.SPAIN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 65.SPAIN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION)
TABLE 66.SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 67.SPAIN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 68.SPAIN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION)
TABLE 69.ITALY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION)
TABLE 70.ITALY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 71.ITALY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 72.ITALY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 73.ITALY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 74.UK ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 75.UK ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 76.UK ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 77.UK ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 78.UK ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 79.RUSSIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 80.RUSSIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 81.RUSSIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 82.RUSSIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 83.RUSSIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 84.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 85.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 86.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 87.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 88.REST OF EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 89.EUROPE ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 90.EUROPE ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 91.EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 92.EUROPE ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 93.EUROPE ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 94.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION) 
TABLE 95.JAPAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 96.JAPAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 97.JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 98.JAPAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 99.JAPAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 100.INDIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 101.INDIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 102.INDIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 103.INDIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 104.INDIA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 105.CHINA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 106.CHINA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 107.CHINA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 108.CHINA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 109.CHINA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 110.PAKISTAN ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 111.PAKISTAN ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 112.PAKISTAN ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 113.PAKISTAN ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 114.PAKISTAN ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 115.VIETNAM ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 116.VIETNAM ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 117.VIETNAM ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 118.VIETNAM ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 119.VIETNAM ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 120.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 121.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 122.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 123.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 124.REST OF ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 125.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 126.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 127.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 128.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 129.ASIA-PACIFIC ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 130.LAMEA ANTIBIOTICS MARKET, BY COUNTRY, 2018-2027 ($MILLION) 
TABLE 131.BRAZIL ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 132.BRAZIL ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 133.BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 134.BRAZIL ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 135.BRAZIL ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 136.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 137.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 138.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 139.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 140.SAUDI ARABIA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 141.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 142.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 143.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 144.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 145.SOUTH AFRICA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 146.TURKEY ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 147.TURKEY ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 148.TURKEY ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 149.TURKEY ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 150.TURKEY ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 151.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 152.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 153.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 154.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 155.REST OF LAMEA ORAL ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 156.LAMEA ANTIBIOTICS MARKET, BY CLASS, 2018-2027 ($MILLION) 
TABLE 157.LAMEA ANTIBIOTICS MARKET, BY APPLICATION, 2018-2027 ($MILLION) 
TABLE 158.LAMEA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2018-2027 ($MILLION) 
TABLE 159.LAMEA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2018-2027 ($MILLION) 
TABLE 160.LAMEA ANTIBIOTICS MARKET, BY DRUG TYPE, 2018-2027 ($MILLION) 
TABLE 161.ABBOTT: COMPANY SNAPSHOT
TABLE 162.ABBOTT: OERATING SEGMENT
TABLE 163.ABBOTT: PRODUCT PORTFOLIO
TABLE 164.ALLERGAN: COMPANY SNAPSHOT
TABLE 165.ALLERGAN: OPERATING SEGMENTS
TABLE 166.ALLERGAN: PRODUCT PORTFOLIO
TABLE 167.ROCHE: COMPANY SNAPSHOT
TABLE 168.ROCHE: OERATING SEGMENT
TABLE 169.ROCHE: PRODUCT PORTFOLIO
TABLE 170.GSK: COMPANY SNAPSHOT
TABLE 171.GSK: OPERATING SEGMENTS
TABLE 172.GSK: PRODUCT PORTFOLIO
TABLE 173.MERCK: COMPANY SNAPSHOT
TABLE 174.MERCK: OPERATING SEGMENTS
TABLE 175.MERCK PRODUCT PORTFOLIO
TABLE 176.MYLAN: COMPANY SNAPSHOT
TABLE 177.MYLAN: OPERATING SEGMENTS
TABLE 178.ALLERGAN: PRODUCT PORTFOLIO
TABLE 179.NOVARTIS: COMPANY SNAPSHOT
TABLE 180.NOVARTIS: OPERATING SEGMENTS
TABLE 181.NOVARTIS: PRODUCT PORTFOLIO
TABLE 182.PFIZER: COMPANY SNAPSHOT
TABLE 183.PFIZER: OPERATING SEGMENTS
TABLE 184.PFIZER: PRODUCT PORTFOLIO
TABLE 185.SANOFI: COMPANY SNAPSHOT
TABLE 186.SANOFI: OPERATING SEGMENTS
TABLE 187.SANOFI: PRODUCT PORTFOLIO
TABLE 188.TEVA: COMPANY SNAPSHOT
TABLE 189.TEVA: OPERATING SEGMENTS
TABLE 190.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.ORAL ANTIBIOTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN THE GLOBAL ORAL ANTIBIOTICS MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.MARKET SHARE ANALYSIS, 2018
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 09.LOW THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE THREAT OF SUBSTITUTIONS
FIGURE 11.HIGH COMPETITIVE RIVALRY
FIGURE 12.BROAD-SPECTRUM PENICILLIN MARKET, 2018–2027 ($MILLION) 
FIGURE 13.MID/NARROW-SPECTRUM PENICILLIN MARKET, 2018–2027 ($MILLION) 
FIGURE 14.CEPHALOSPORIN ANTIBIOTICS MARKET, 2018–2027 ($MILLION) 
FIGURE 15.OTHER BETA LACTAM & BETA LACTAMASE INHIBITORS ANTIBIOTICS MARKET, 2018–2027 ($MILLION) 
FIGURE 16.COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 17.COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR QUINOLONES, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 18.COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR MACROLIDES, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 19.COMPARATIVE ANALYSIS OF ANITBIOTICS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 20.ORAL ANTIBIOTICS MARKET FOR UPPER RESPIRATORY TRACT INFECTIONS, 2018–2027 ($MILLION) 
FIGURE 21.ORAL ANTIBIOTICS MARKET FOR LOWER RESPIRATORY TRACT INFECTIONS, 2018–2027 ($MILLION) 
FIGURE 22.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 23.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR URINARY TRACT INFECTIONS, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 24.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY COMBINATION, 2018–2027 ($MILLION) 
FIGURE 25.ORAL ANTIBIOTICS MARKET FOR DENTAL, BY MONOTHERAPIES, 2018–2027 ($MILLION) 
FIGURE 26.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR DENTAL, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 27.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 28.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR NATURAL, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 29.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 30.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR SYNTHETIC, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 31.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ORAL ANTIBIOTIC, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 32.COMPARATIVE ANALYSIS OF ORAL ANTIBIOTICS MARKET FOR MID/NARROW-SPECTRUM ORAL ANTIBIOTIC, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 33.COMPARATIVE ANALYSIS OF BRANDED ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 34.COMPARATIVE ANALYSIS OF GENERIC ORAL ANTIBIOTICS MARKET, BY COUNTRY, 2018 & 2027 ($MILLION) 
FIGURE 35.ABBOTT: NET SALES, 2017–2019 ($MILLION) 
FIGURE 36.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 37.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.ALLERGAN: NET SALES, 2017–2019 ($MILLION) 
FIGURE 39.ALLERGAN: REVENUE SHARE, BY SEGMENT, 2019(%)
FIGURE 40.ROCHE: NET SALES, 2017–2019 ($MILLION) 
FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.GSK: NET SALES, 2017–2019 ($MILLION) 
FIGURE 44.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.MERCK: NET SALES, 2017–2019 ($MILLION) 
FIGURE 47.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.MYLAN: NET SALES, 2017–2019 ($MILLION) 
FIGURE 50.MYLAN: REVENUE SHARE, BY REGION, 2017 (%)
FIGURE 51.NOVARTIS: NET SALES, 2017–2019 ($MILLION) 
FIGURE 52.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 54.PFIZER: NET SALES, 2017–2019 ($MILLION) 
FIGURE 55.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 56.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 57.SANOFI: NET SALES, 2017–2019 ($MILLION) 
FIGURE 58.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 59.SANOFI: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 60.TEVA: NET SALES, 2017–2019 ($MILLION) 
FIGURE 61.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 62.TEVA: REVENUE SHARE, BY REGION, 2019 (%)

 
 

This section provides various opinions of top-level CXOs in the oral antibiotics market. According to several interviews conducted, the field of oral antibiotics is gaining popularity, owing to its ease of use and convenience for patients. 

As per CXOs, rise in infectious diseases, growth in initiatives by pharma companies to enhance antibiotics R&D, and technological innovations in oral antibiotics significantly boost the growth of the oral antibiotics market. However, development of antibiotic resistance, driven by misuse of antibiotics, and increase in drug approval costs are expected to hinder the market growth.

In addition, rise in consumption of antibiotics in low and middle-income countries (LMICs), increase in prevalence of infectious diseases, development of novel approaches for new antibiotics to treat bacterial infections, and large number of clinical trials are projected to drive the market growth during the forecast period. 

The CXOs further added that the market is saturated and is growing at a steady rate in developed nations. Asia-Pacific is expected to remain dominant during the forecast period, owing to increase in consumption of antibiotics, lower cost of antibiotics, and high prevalence of bacterial infections in developing countries. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, owing to rise in antimicrobial resistance, which leads pharmaceutical companies toward R&D for next generation antibiotics. In addition, wide availability of advanced systems supplements the growth of the market. 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total value of oral antibiotics market was $ 18,861.70 million in 2019.

A. The forecast period in the report is from 2020-2027.

A. The market value of oral antibiotics market in 2020 was $24,256.10 million.

A. The base year calculated is 2018 in the report.

A. As per the key industry leaders, rise in incidence of infectious diseases cases, Increase in consumption in low-and middle-income countries (LMICs)increasing R&D initiatives to develop novel technologies and Development of novel approaches will drive the oral antibiotics market

A. Development of novel approaches in the market is expected to drive the market growth during the forecast period.

A. The growth % of the Autoinjectors market is 2.7%.

A. Beta lactam and lactamase inhibitors segment holds the maximum market share.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Oral Antibiotics Market, by Class

  • Online Only
  • $3,990
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,433
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,599
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $7,447
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,385
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/m
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts